I'll just say, yesterdays poster was awesome. VERY well put together.
I was just curious. There really is no comparison since in 2013 it was "A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile,
a novel p53 targeted therapy, in patients with advanced solid tumors"
and yesterday... "Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies"
Quote: